CNS

#AI #Cancer #CNS #FDA #Lantern Pharma #Solid tumours

FDA clearance of IND application for solid tumour drug 

Lantern Pharma, an AI company developing targeted and transformative cancer therapies, has received clearance from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application for LP-184, which is being developed for multiple advanced solid tumours and central nervous system (CNS) cancers.   The… Read More

#News

Heart monitor
#Cardiovascular disease #CNS #Heart failure #Sleep apnoea #University of Auckland #University of São Paulo

Novel drug shows promise for heart failure and sleep apnoea

A novel drug is showing promise for alleviating heart failure, a common condition associated with sleep apnoea and a reduced lifespan. The drug, known as AF-130, was tested by scientists at University of Auckland, New Zealand and the University of São Paulo, Brazil. They found it… Read More

#News

Genetic engineering
#Cell and gene therapy #CNS #Gene editing #Gene therapy #Genetics / genomics #Paediatrics #Stem cells

Gene therapy for ‘childhood dementia’ shows promise

An investigational gene therapy for Sanfilippo syndrome – which leads to a form of childhood dementia – has shown promising early results in a proof-of-concept study.  The study found that four out of five patients diagnosed with Sanfilippo have continued to gain cognitive skills in line with… Read More

#Editor's Choice #News

Remyelination
#Acquisition #CNS #Drug discovery #Pheno Therapeutics #Phenomics #Phenotyping

Pheno Therapeutics buys rights to potential remyelination drug

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology and promote remyelination. Read More

#Business & Investment #News

Central nervous system
#CNS #Collaboration #Genetics / genomics #Partnership #Pharmaceuticals #Research & development #Target identification

Collaboration will focus on therapy targets for CNS disorders

PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership.   The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono.  PrecisionLife analyses multi-modal datasets including genomic, clinical, and epidemiological data… Read More

#Business & Investment #News

Map of Europe
#CNS #Collaboration #European Medicines Agency #License agreement #Orphan drugs

Alliance will provide a new therapy for rare CNS disease 

Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe.  The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy… Read More

#News

#CNS #Depression #Start-ups

Start-up looks to treat depression  

A new start-up has launched with an aim of developing therapeutics that address synaptic dysfunction in patients suffering from central nervous system (CNS) disorders.   Gate Neurosciences was founded in 2019 by a team of neuroscientists with the goal of addressing the urgent need for more effective treatments for CNS disorders,… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #CNS #Drug discovery

Collaboration seeks innovative treatments for CNS disorders

Blue Oak Pharmaceuticals, an innovator in the discovery of transformative CNS drugs, and Exscientia, a clinical-stage Artificial Intelligence (AI) drug-discovery company, have announced an innovative drug-discovery collaboration to treat brain disorders. This collaboration combines Blue Oak’s therapeutic area expertise and ability to design novel, CNS focused privileged chemotypes with Exscientia’s… Read More

#News